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Themain lesion inParkinsondisease (PD) is loss of substantia
nigra dopaminergic neurons. Levodopa (L-DOPA) is the most
widely used therapy, but it does not arrest disease progression.
Some possible contributing factors to the continuing neuronal
loss are oxidative stress, including oxidation of L-DOPA, and
neurotoxins generated by locally activated microglia and astro-
cytes. A possible method of reducing these factors is to produce
L-DOPA hybrid compounds that have antioxidant and antiin-
flammatory properties. Here we demonstrate the properties of
four such L-DOPA hybrids based on coupling L-DOPA to four
different hydrogen sulfide-donating compounds. The donors
themselves were shown to be capable of conversion by isolated
mitochondria toH2Sor equivalent SH ions.This capabilitywas
confirmed by in vivo results, showing a large increase in intra-
cerebral dopamine and glutathione after iv administration in
rats. When human microglia, astrocytes, and SH-SY5Y neuro-
blastoma cells were treated with these donating agents, they all
accumulatedH2S intracellularly as did their derivatives coupled
to L-DOPA. The donating agents and the L-DOPA hybrids
reduced the release of tumor necrosis factor-, interleukin-6,
and nitric oxide from stimulatedmicroglia, astrocytes as well as
the THP-1 and U373 cell lines. They also demonstrated a neu-
roprotective effect by reducing the toxicity of supernatants from
these stimulated cells to SH-SY5Y cells. L-DOPA itself waswith-
out effect in any of these assays. The H2S-releasing L-DOPA
hybrid molecules also inhibited MAO B activity. They may be
useful for the treatment of PD because of their significant anti-
inflammatory, antioxidant, and neuroprotective properties.
The pathogenesis of Parkinson disease (PD)2 results primar-
ily from loss of neurons, especially dopaminergic neurons of the
substantia nigra zona compacta. Levodopa (L-DOPA) therapy is
the most widely used treatment because it helps to compensate
for the deficiency of dopamine. Whereas L-DOPA treatment is
very successful in the early stages of PD, it does not arrest dis-
ease progression, and in the long term there are unwanted side
effects, such as the development of dyskinesias (1–3). Many
previous studies have investigated the reasons for such long
term problems. One suggested mechanism is loss of neurons
induced by oxidative stress, including the oxidation of L-DOPA
(4–6). Another is persisting neuroinflammation caused by acti-
vatedmicroglia and astrocytes (7–10). Hybridmolecules which
combine L-DOPAwith antioxidant and antiinflammatory moi-
eties might therefore have therapeutic potential.
Hydrogen sulfide (H2S) has traditionally been regarded as
nothing more than a noxious gas with an extremely unpleasant
odor. But it is an essential body product. In solution it is a
powerful reducing agent with endogenous antioxidant and
neuroprotective properties. It is synthesized by the action of
two enzymes, cystathione -synthase (CBS) and cystathione
-lyase (CGL). CBS is the main enzyme producing H2S in the
brain (11, 12), whereas CGL is themain enzyme producing it in
vascular tissue (13). Much attention has been given to this mol-
ecule because it hasmultiple physiological and pathophysiolog-
ical functions in body organs. A protective role for H2S in neu-
rons against oxidative stress has been reported (14). It has also
been demonstrated that H2S induces alterations in calcium
channels [Ca2]i in astrocytes and microglia (15, 16) and
enhances both NMDA receptor-mediated neurotransmission
and long term potentiation (17).
Oxidative stress and neuronal cell death in PD is associated
with microglial activation, which involves the release of pro-
inflammatory cytokines and free radicals (9, 10). Recently, pro-
tective functions of H2S against LPS-induced inflammation in
primary cultured and immortalized microglia have been
reported (12, 18, 19). Such a protective effect has been demon-
strated in vivo in the 6-OHDA rat model of Parkinson disease
(20).
To date there are no disease-modifying drugs for the treat-
ment of PD. As an approach to the development of next gener-
ation agents, we have prepared hybrid compounds designed to
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combine the dopamine replacement properties of L-DOPA
with the neuroprotective properties of H2S donors.
In this investigation, we synthesized four H2S-releasingmoi-
eties (ACS48, ACS50, ACS5, and ACS81) and examined
whether they release H2S or equivalent SH ions in both glia
and neurons. The sulfurated moieties were chosen among
those resembling the structures of known H2S-releasing com-
pounds such as the dithiolethione ADT-OH (21) and diallyl-
disulfide (22). We coupled these moieties to L-DOPA methyl
ester through an amide linkage to create different lipophylic
compounds potentially able to release H2S. The four hybrid
moleculeswere designatedACS83,ACS84,ACS85, andACS86.
The structure of the four donors and the four hybrid molecules
are shown in Fig. 1. We made a pilot in vivo test with ACS84 to
confirm that these types of compounds can reach the brain.
We found that it reached the brain and that it produced an
increase of intracerebral dopamine and glutathione. We tested
the effects of all these compounds on prevention of neuronal
cell death induced by stimulation of four types of cultured
human glial cells: astrocytes, microglia, and the THP-1 and
U373 cell lines. NaSH was used as the standard H2S donor for
comparative purposes. We found that these hybrid molecules
were able to release H2S or equivalent ions from all cell types
tested, and from mitochondria isolated from U373 cells.
EXPERIMENTAL PROCEDURES
Materials—All reagents were purchased from Sigma unless
otherwise stated. The following substances were applied to the
cell cultures: bacterial LPS (from Escherichia coli 055:B5) and
human recombinant interferon- (INF) (from Bachem Cali-
fornia, Torrance, CA). The following substances were used in
the assays: diaphorase (EC 1.8.1.4, from Clostridium kluyveri,
5.8 units/mg solid), p-iodonitrotetrazolium violet (INT), nico-
tinamide adenine dinucleotide (NAD), and MTT (3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide).
Chemistry—Some of the sulfurated intermediates were
already known and were prepared according to the literature.
All novel compounds synthesized were characterized by melt-
ing point (m.p.; Buchi apparatus), 1H NMR spectra (Varian
Mercuri 300VX spectrometer) and high-resolution mass spec-
tra (HRMS; APEX II ICR-FTMS Bruker Daltonics mass spec-
trometer, ESI). Log P were calculated by ChemDraw Ultra 9.0
software.
ACS48 (4-(3-thioxo-3H-1,2-dithiol-4-yl)-benzoic acid) was
obtained by hydrolysis of the corresponding methyl ester,
which was synthesized as previously described by Adelaere
(23). ACS50 ([2-methoxy-4-(3-thioxo-3H-1,2-dithiol-5-yl)-
phenoxy]acetic acid, m.p. 198–200 °C) was obtained by acidic
hydrolysis of the corresponding methyl ester, which was
synthesized as described by Lozac’h and Mollier (24). ACS5
(1,3-dithiole-2-thioxo-4-carboxylic acid) was synthesized as
previously described by Dartigues et al. (25). ACS81 (3-(prop-
2-en-1-yldisulfanyl)propanoic acid) was synthesized as follows:
to a stirred solution of diallyl disulfide (2.4g; 13.6 mmol) in a
mixture of ether (10 ml) and methanol (20 ml), under nitrogen
FIGURE 1. The structure and synthetic scheme of H2S-releasing agents ACS 48, ACS 50, ACS 5, and ACS 81 and the H2S-releasing L-DOPA derivatives,
ACS83, ACS84, ACS85, and ACS86.
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atmosphere at room temperature, was added a solution of
3-mercaptopropanoic acid (0.49 g, 4.6 mmol) in ether (5 ml),
followed by a solution of 10 M NaOH (0.46 ml). The reaction
mixture was stirred at room temperature for 24 h and, after
evaporation of the solvents under reduced pressure, the crude
compound was taken up with ether and 1 N HCl. After separa-
tion of the organic phase and evaporation of the ether, the res-
iduewas purified by column chromatography on silica gel, elut-
ing with CH2Cl2/CH3COOC2H5 (60:40). A colorless oil was
obtained (520 mg; yield 63%). 1H NMR (CDCl3):  5.91–5.77
(m, 1H); 5.24–5.13 (m, 2H); 3.33 (d, J 7.30Hz, 2H); 2.92 (t, J
6.90 Hz, 2H); 2.80 (t, J  6.90 Hz, 2H). HMRS (ESI) m/z cal-
culated for C6H10O2S2Na [MNa]: 201.00144; found:
201.00147.
Synthesis of Sulfurated Derivatives of L-DOPA Methyl Ester
(ACS83, ACS84, ACS85, and ACS86)—L-DOPA methyl ester
hydrochloride (200 mg, 0.8 mmol), 1-hydroxybenzotriazole
(HOBt, 185 mg; 1.2 mmol) and 1-ethyl-3-(3-dimethylamino-
propyl)carbodiimide hydrochloride (EDAC, 232 mg; 0.96
mmol) were added to a solution of the proper sulfurated com-
pounds (ACS48, or ACS50, or ACS5, or ACS81; 0.8 mmol) in
anhydrous N,N-dimethylformamide (DMF) (4 ml) and, after
the addition of triethylamine (0.22 ml; 1.6 mmol), the solution
was stirred at room temperature for 24 h under a nitrogen
atmosphere. After evaporation of DMF, the residue was dis-
solved in dichloromethane and the organic solution was
washed sequentially with water, 1 N HCl, and water and finally
dried with anhydrous Na2SO4 and evaporated to dryness. The
crude compound was purified by flash chromatography (silica,
CH2Cl2/MeOH, 98:2).
Methyl 3-(3,4-dihydroxyphenyl)-2-(4-(3-thioxo-3H-1,2-di-
thiol-4-yl)benzamido)propanoate (ACS83)—Yield 35%. M.p.
160–165 °C. 1HNMR (DMSO-d6):  9.21 (s, 1H); 8.81 (d, J
7.63 Hz, 1H, collapses with D2O); 8.74 (s, 1H, collapses with
D2O); 8.66 (s, 1H, collapses withD2O); 7.85 (d, J 8.21Hz, 2H);
7.65 (d, J 8.21 Hz, 2H); 6.65 (d, J 1.76 Hz, 1H); 6.59 (d, J
8.21 Hz, 1H); 6.51 (dd, J  1.76, 8.21 Hz, 1H); 4.57–4.50 (m,
1H); 3.62 (s, 3H); 2.99–2.85 (m, 2H). HMRS (ESI) m/z calcu-
lated for C20H17NO5S3Na [MNa]: 470.01611; found:
470.01620. Calc. log P: 3.58.
Methyl 3-(3,4-dihydroxyphenyl)-2-(2-(2-methoxy-4-(3-
thioxo-3H-1,2-dithiol-5-yl)phenoxy)acetoamido)propanoate,
(ACS84)—Yield 53%. M.p. 153–155 °C. 1H NMR (DMSO-d6):
 8.79 (s, 1H, collapses with D2O); 8.75 (s, 1H, collapses with
D2O); 8.29 (d, J 7.91Hz, 1H, collapses withD2O); 7.85 (s, 1H);
7.42–7.37 (m, 2H); 6.77 (d, J 8.21Hz, 1H); 6.61 (d, J 7.91Hz,
1H); 6.56 (d, J 2.05 Hz, 1H); 6.41 (dd, J 2.05, 7.91 Hz, 1H);
4.65–4.54 (m, 2H); 4.51–4.43 (m, 1H); 3.85 (s, 3H); 3.61 (s, 3H);
2.91–2.72 (m, 2H). HMRS (ESI) m/z calculated for
C22H21NO7S3Na [MNa]: 530.03724; found: 530.03660.
Calc. log P: 3.19.
Methyl 3-(3,4-dihydroxyphenyl)-2-(2-thioxo-1,3-dithiole-4-
carboxamido)propanoate, (ACS85)—Yield 56%. M.p. 66–70 °C.
1H NMR (DMSO-d6):   9.24 (d, 1H, J  7.92 Hz, collapses
with D2O); 8.76 (s, 1H, collapses with D2O); 8.71 (s, 1H, col-
lapses with D2O); 8.31 (s, 1H); 6.61–6.58 (m, 2H); 6.46 (dd, J
1.76, 7.92 Hz, 1H); 4.47–4.39 (m, 1H); 3.61 (s, 3H); 2.96–2.76
(m, 2H). HMRS (ESI) m/z calculated for C14H13NO5S3Na
[MNa]: 393.98481; found: 393.98524. Calc. log P: 1.68.
Methyl 2-(3-(allyldisulfanyl)propanamido)-3-(3,4-dihy-
droxyphenyl)propanoate, (ACS86)—Yield 50%. Semisolid; 1H
NMR (DMSO-d6):  8.74 (s, 1H, collapses with D2O); 8.68 (s,
1H, collapses withD2O); 8.34 (d, J 7.92Hz, 1H, collapses with
D2O); 6.59 (d, J 7.91 Hz, 1H); 6.54 (d, J 2.06 Hz, 1H); 6.41
(dd, J  2.06, 7.91 Hz, 1H,); 5.86–5.72 (m, 1H); 5.20–5.09 (m,
2H); 4.37–4.30 (m, 1H); 3.56 (s, 3H); 3.35 (d, J 7.33 Hz, 2H);
2.82–2.64 (m, 4H); 2.49–2.46 (m, 2H). HMRS (ESI)m/z calcu-
lated for C16H21NO5S2Na [MNa]: 394.07534; found:
394.07469. Calc. log P: 2.32.
Animal Treatments and Sample Processing—Sprague-Daw-
ley rats (350–400 g) were purchased from Charles River. Rats
received administration of ACS84 dissolved in 500 l of
PEG400 via the caudal vein. After 1 h, animals were anesthe-
tized with pentobarbital (60 mg/kg), and blood was collected
from the abdominal aorta in tubes containing 50 mg/ml
K3EDTA and immediately processed. Plasma was obtained by
centrifugation of blood at 10,000 g for 15 s and immediately
deproteinized by addition of 4 volumes of acetonitrile (ACN).
The brain was then removed and cut longitudinally to obtain 2
equal halves. One half was homogenized in 5 volumes of 4%
(w/v) trichloroacetic acid containing 1 mM K3EDTA for the
analyses of glutathione and dopamine. The other half was
homogenized in 5 volumes of a solution of 80% (v/v) acetoni-
trile to measure ACS84 and its metabolites. All animal manip-
ulations were made in accordance with the European Commu-
nity guidelines for the use of laboratory animals. The
experiments were authorized by the local ethical committee.
HPLC Analyses of ACS84 Metabolites—For the determina-
tion of ACS84, ACS84-a, and ACS50, both brain and plasma
samples were centrifuged to discard acetonitrile-denatured
proteins (10,000  g for 2 min). The clear supernatants were
then diluted 1:1 with 0.05% trifluoroacetic acid, loaded onto an
HPLC (Zorbax Eclipse XDB-C18 column, 4.6 150mm, 5m,
Agilent Technologies, Milan, Italy) and separated by the appli-
cation of a trifluoroacetic acid/acetonitrile solution: 0–9 min,
40% ACN in 0.05% (v/v) trifluoroacetic acid; 9–10 min,
40–90% ACN gradient. Analytes were detected at 435-nm
wavelength. The identity of the peakwas determined by analyz-
ing plasma samples spiked with the respective authentic com-
pounds. Calibration curves were generated in the 0.2–100 M
range by addition of ACS50, ACS84, or ACS84-a to rat plasma
samples obtained from untreated animals.
HPLC Analyses of Dopamine and Glutathione for in Vivo
Analysis—For the determination of GSH and dopamine, sam-
ples were centrifuged to discard proteins (10,000 g for 2min).
Dopamine was measured on the clear supernatant by
UV-HPLC with fluorescence detection (excitation at 270 nm,
emission at 320 nm, Zorbax Eclipse XDB-C18 column, 4.6 
150mm, 5m). Separationwas carried out by the application of
an isocratic run: 5% (v/v) methanol in 0.05% (v/v) trifluoroace-
tic acid (26). Another aliquot of the supernatant (0.1 ml) was
brought to pH8.0 with 15 l of 2 M Tris, and then 3 l of 40
mM monobromobimane (mBrB) were added for the analysis of
GSH. After 10 min of incubation in the dark, samples were
H2S-releasing L-DOPAs and Glial Activation
17320 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 285•NUMBER 23•JUNE 4, 2010












Supplemental Material can be found at:
acidified and analyzed by HPLC (Zorbax Eclipse XDB-C18 col-
umn, 4.6 150 mm, 5 m) as previously described (27).
Cell Culture and Experimental Protocols—The human
monocyte THP-1 and astrocytoma U373 cell lines were
obtained from the American Type Culture Collection (ATCC).
The human neuroblastoma SH-SY5Y cell line was a gift from
Dr. R. Ross, FordhamUniversity, NY. These cells were grown in
DMEM/F12medium containing 10% fetal bovine serum (FBS),
100 international units/ml penicillin, and 100 g/ml strepto-
mycin (Invitrogen, Carlsbad, CA) under humidified 5% CO2
and 95% air. Human astroglial andmicroglial cells were isolated
from surgically resected temporal lobe tissue. The procedures
described previously for obtaining pure cultures of microglia
and astrocytes were followed (28).
Experimental Protocol—Human astrocytes, U373 astrocy-
toma cells and THP-1 cells (5  105 cells), as well as human
microglial cells (5 104 cells) were seeded into 24-well plates in
1 ml of DMEM/F12medium containing 5% fetal bovine serum.
The CBS inhibitor hydroxylamine (1 mM) was added to inhibit
endogenous production of H2S by CBS. L-DOPA, ()-deprenyl
or H2S-releasing moieties were then added at a concentration
of 10 M. Incubation of the mixtures was carried out for 2, 4, 8,
or 12 h. The H2S-releasing moieties included NaSH, ACS 48,
ACS50, ACS5, ACS81, and ADT-OH (21), as well as the hybrid
molecules ACS83, ACS84, ACS85, and ACS86. Cells were
washed with phosphate-buffered saline (PBS) twice and
replated in 800l DMEM/F12mediumcontaining 5%FBS.The
cells were then incubated at 37 °C for 2 days in the presence of
inflammatory stimulants. For microglia and THP-1 cells, the
stimulants were LPS at 1 g/ml and IFN at 333 units/ml. For
astrocytes and U373 cells, the stimulant was IFN alone at 150
units/ml. A companion set of cells was incubated in medium
without inflammatory stimulants. After incubation, the super-
natants (400 l) were transferred to undifferentiated human
neuroblastoma SH-SY5Y cells (2 105 cells per well). The cells
were incubated for a further 72 h, and MTT and LDH assays
performed as described below.
SH-SY5Y Cell Viability Assays—The viability of SH-SY5Y
cells following incubation with glial cell supernatants was eval-
uated by the LDH release and MTT assays as previously
described in detail (29). For the LDH assay, the amount of LDH
released was expressed as a percentage of the value obtained in
comparative wells where cells were 100% lysed by 1% Triton
X-100. For theMTTassay, data are presented as a percentage of
the value obtained from cells incubated in fresh medium only.
Measurement of TNF and IL-6 Release—Cytokine levels
were measured in cell-free supernatants following 48 h of incu-
bation of THP-1 cells, U373 cells, microglial cells, or astrocytes.
The cell stimulation protocols were the same as used for mea-
suring H2S generation. Quantitation was performed with
ELISA detection kits (Peprotech, NJ) following protocols
described by the manufacturer.
Measurements of Nitrite Release—Accumulation of NO2 as
an indicator ofNO synthesis was assayed by the standardGriess
reaction. After stimulation of cells for 48 h, the media were
centrifuged, and the cell-free supernatants mixed with an equal
volume of Griess reagent (Sigma). Samples were incubated at
room temperature for 15 min, and the fluorescence read at an
excitation of 380 nm and an emission of 540 nm using a plate
reader.
Preparation of Mitochondria from U373 Cells—Preparation
of functional mitochondria from human U373 cells was per-
formed as described previously (30). Briefly, U373 cells were
detached from a tissue culture flask using a cell scraper and
were then transferred to 50 ml Falcon tubes for centrifugation
(2,000 rpm for 10 min) at 4 °C. After their supernatants were
discarded, cells were resuspended in 30 ml of ice-cold mito-
chondria isolation buffer (10mMTris-MOPS, 1mMEGTA, and
0.2 M sucrose, pH 7.4), and homogenized with a glass/Teflon
potter homogenizer. The homogenates were transferred to 50
ml Falcon tubes for centrifugation (2,000 rpm for 10 min) at
4 °C. The supernatants were collected to perform high-speed
centrifugation (30,000 rpm, 10 min) at 4 °C. After the superna-
tants were discarded, the pellets were resuspended with 5 ml of
ice-cold mitochondria isolation buffer and centrifuged again
(30,000 rpm, 10min). The pellets including mitochondria were
resuspended very gently with 5 ml of PBS for H2S measure-
ments in the presence of H2S releasers (ADT-OH, ACS48,
ACS50, ACS5, and ACS81).
Measurement of H2S Levels—H2S levels weremeasured using
a previously described method (21). To suppress endogenous
production of H2S by CBS, all experiments were done with 1
mM of the specific CBS inhibitor hydroxylamine added to the
solutions. Two sets of experiments were conducted: one in
which the THP-1 cells and U373 cells were unstimulated and a
second where they were stimulated with inflammatory media-
tors for 48 h. For THP-1 cells, the stimulation was LPS at 1
g/ml and IFN at 333 units/ml, and for U373 cells it was IFN
at 150 units/ml. The cells in each case were treated with 1 mM
hydroxylamine plus NaSH, ADT-OH, ACS83, ACS84, ACS85,
or ACS86 (10 M each) for 2, 4, 8, and 12 h. Following treat-
ment, they were homogenized in 250 l of ice-cold 100 mM
potassiumphosphate buffer (pH7.4) containing trichloroacetic
acid (10% w/v). Zinc acetate (1% w/v, 250 l) was injected to
trap the generated H2S. A solution of N,N-dimethyl-p-
phenylenediamine sulfate (20 M; 133 l) in 7.2 M HCl and
FeCl3 (30 M; 133 l) in 1.2 M HCl was added. Absorbance at
670 nm of the resulting mixture (300 l) was determined after
10 min using a 96-well microplate reader (Bio-Rad). The H2S
concentration of each sample was calculated against a calibra-
tion curve ofNaSH (1–250M) and results expressed asmol/g
protein or nmol/ml.
GSH Level in Glial Cells in Vitro—The GSH level was
assessed by the method of Hissin and Hilf (31). This assay
detects reduced glutathione (GSH) by its reaction with
o-phthalaldehyde (OPT) at pH 8.0. Cells (106) in 1.5-ml tubes
were washed twice with PBS, and treated with 200 l of 6.5%
(w/v) trichloroacetic acid. Themixturewas incubated on ice for
10 min and centrifuged (13,000 rpm, 1 min). The supernatant
was discarded, and the pellets were resuspended in 200 l of
ice-cold 6.5% (w/v) trichloroacetic acid and centrifuged again
(13,000 rpm, 2 min). Supernatants (7.5 l) were transferred to
96-well plates containing 277.5l phosphate-EDTAbuffer (pH
8.0) in 1 M NaOH solution. Then 15 l of OPT (1 mg/ml in
methanol) was added. The reaction mixture was incubated in
the dark at room temperature for 25 min. The fluorescence at
H2S-releasing L-DOPAs and Glial Activation
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350 nm excitation/420 nm emission was measured in a multi-
well plate reader. The concentration was calculated from a
standard curve using a serial dilution of reduced GSH.
Activity ofMonoamineOxidaseAandB—Activities ofmono-
amine oxidaseA andB (MAOAandMAOB, respectively) after
SH-SY5Y cells were exposed to glial-conditionedmedium for 1
day were measured using a kit (Amplex Red monoamine oxi-
dase kit,Molecular Probes Inc., Eugene,OR). Experimentswere
performed as described by the manufacturer.
Data Analysis—The significance of differences between data
sets was analyzed by Student’s t test and one-way or two-way
ANOVA.Multiple group comparisons were followed by a post-
hoc Bonferroni test.
RESULTS
First, we evaluated the release rate in vivo of the H2S donor
from ACS84, a typical L-DOPA hybrid compound, adminis-
tered intravenously (40 mg/kg) into rats. Table 1 demonstrates
the formation of the main metabolites of ACS84. After 1 h,
almost all of the ACS84 had disappeared from plasma with the
concomitant appearance of both its demethylated derivative
(ACS84-a) and of its dithiolethione moiety (ACS50). Measure-
ments performed at earlier times from the treatments indicate
that demethylation of ACS84 occurs rapidly, whereas the cleav-
age of the amide bond between dithiolethione and L-DOPA
occurs more slowly (data not shown). Low micromolar or sub-
micromolar concentrations of ACS84 and its main metabolites
were found in brain 1 h after administration.
Dopamine levels in brain were increased 2.2-fold by treat-
mentwithACS84. Interestingly, GSH, a known antioxidant and
neuroprotective agent (32) was increased 1.4-fold by this treat-
ment. Although treatment with an equimolar dose of L-DOPA
also increased dopamine levels in brain, the increase was only
by 1.6-fold, and there was no increase in GSH (Table 2). These
data encouraged us to pursue in vitro experiments to determine
whether H2S-releasing L-DOPA hybrid compounds can lead to
accumulation of H2S in both glia and SH-SY5Y cells, and what
effects this release might produce.
We commenced by examining the rate of cleavage of the
H2S-releasing moieties (ADT-OH, ACS48, ACS50, ACS5,
and ACS81) under extracellular conditions. We tested
release from PBS, the DMEM/F12 culture medium, and
human serum. We then compared this with the rate of
uptake and cleavage intracellularly in THP-1, U373, and
SH-SY-5Y cells (Fig. 2).
In PBS and the DMEM/F12 medium, H2S was released very
slowly, reaching only 10% of the total amount available after
48 h (see Fig. 2B for ACS50 as a representative in DMEM/F12
medium and for ACS50 in PBS). Human serum caused a more
rapid release with 50% of the potential being attained in 4.5–18
h. (ADT-OH, 4.5 h; ACS5,6 h; ACS 48, 6 h; ACS 50, 12 h; and
ACS 81, 18 h) indicating the presence of weakly active cleaving
enzymes in human serum. In contrast, NaSH, the model H2S
donor, released its full potential immediately. It then showed a
slow decay, declining by about 10% over 48 h (see supple-
mental Fig. S1,B,D, and F), indicatingminor decay of SH ions.
These data demonstrate that the H2S donating molecules are
stable extracellularly, and, if administered in vivo, should be
able to reach their target cells relatively intact.
Fig. 2 also indicates what happens when the H2S donors do
reach their target cells. The data show intracellular levels ofH2S
in THP-1, SH-SY5Y, and U373 cells after being exposed to 10
Mof theH2S donors. H2S generated from the donormolecules
slowly increased in the cytoplasm of THP-1 and SH-SY5Y cells
over 48 h. Fig. 2 shows data from ACS50 as a representative of
the S-donor compounds. All the H2S-donor compounds gave
highly similar results. For U373 cells, the conversion was more
robust than for THP-1 and SY-SY5Y cells with a maximum
being reached by 12 h, after which there was a slow decline (Fig.
2A). The intracellular H2S levels reflect the net effect of at least
three mechanisms: uptake of donors into the cells; intracellular
cleavage of the molecules; and intracellular metabolism of the
H2S generated. The other H2S-releasing compounds ACS48,
ACS5, and ACS81 showed the same release kinetics in all cells
tested (see supplemental Fig. S1), as did the S-DOPA derivative
ACS83 (see supplemental Fig. S2).
These data establish that all the moieties are metabolized
within each cell type to generate H2S. To explore a possible
mechanism, we purified functional mitochondria from U373
TABLE 1
Levels of intact molecule and its metabolites in plasma and brain 1 h after iv rat administration of 40 mg/kg ACS 84
Plasma Brain
ACS84 ACS84-a ACS50 ACS84 ACS84-a ACS50
M mean S.E. M mean S.E.
1.1137 0.0867a 6.7267 0.8933 58.9333 3.6988 0.1230 0.0227 0.3497 0.0568 1.3227 0.2476
a Values are mean S.E., n 4.
TABLE 2
Dopamine, L-DOPA, and GSH levels in brain and/or plasma 1 h after iv rat administration of 40 mg/kg ACS84 or an equimolar dose of L-DOPA
Values are mean S.E., n 4. One-way ANOVA test was carried out to evaluate the significance of differences.
Treatments Plasma BrainDopamine L-DOPA Dopamine L-DOPA GSH
M M M M M
ACS84 2.17 0.52a 0 13.2 1.3a 0.277 0.2775a 2402 39.3a
L-DOPA 29.2 3.8b 10.2 2.8b 9.60 0.08b 2.00 0.775b 1479 34
Vehicle 0 0 5.97 0.6 0 1670 60
a p 0.01 for ACS84 group compared with vehicle group.
b p 0.01 for L-DOPA group compared with ACS84 group.
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cells. All mitochondria contain molecules which have a high
reducing potential such as NADH, FADH2, and cytochromes.
As shown in Fig. 3, all the donormoieties, but not ()-depre-
nyl, a classical inhibitor of monoamine oxidase B, were metab-
olized to release H2S within 60 min by the mitochondria. Very
similar results were obtained with the four different S-DOPA
compounds (see supplemental Fig. S3). The data indicate a
potential mechanism by which H2S is generated intracellularly
from the donor moieties.
Within cells, the most important reducing agent is gluta-
thione (GSH). To determine whether the H2S donors were
affecting GSH levels, we measured [GSH]i in SH-SY5Y cells
exposed to the four different S-DOPAs (10 M each) for 8 h.
Equal concentrations of L-DOPA and NaSH were used as
negative and positive controls, respectively. The results are
shown in Fig. 4A. Treatment with NaSH and the S-DOPAs
increased [GSH]i in SH-SY5Y cells under normal conditions by
1.5-fold (p  0.01). We then exposed the cells for 1 day to
conditioned medium from stimulated THP-1 cells (LPS/IFN
for 2 days) or U373 cells (IFN for 2 days). This treatment
caused a huge decrease in [GSH]i (90% decrease, p  0.01).
NaSH and the four H2S-releasing S-DOPAs significantly atten-
uated this decrease (p  0.01). Nevertheless, the values were
still significantly lower than those obtained fromcontrolmedia.
These data establish that H2S generated from the donor com-
pounds is significantly converted into the antioxidant [GSH]i
and that this [GSH]i is significantly depleted by exposure to
supernatants from glial cells that have received inflammatory
stimulation.
Fig. 4, B andC demonstrates the changes inMAOA and B in
SH-SY5Y cells in the presence of NaSH, L-DOPA, and the four
H2S-releasing S-DOPAs. SH-SY5Y cells express both MAO A
and MAO B, the latter accounting for 75% of the total MAO
activity. Treatment with NaSH or four different S-DOPAs (10
M each) for 8 h reduced the activity of MAO B, but not MAO
A. There was no effect of L-DOPA. The decreases were about
85% (p 0.01) after exposure of SH-SY5Y cells to media from
unstimulated THP-1 or U373 cells and about 65% after expo-
sure to medium from THP-1 or U373 cells stimulated for 24 h
(p 0.01). These data establish that all the S-DOPAs are selec-
tive MAO B inhibitors.
We next investigated the effects of 1, 3, 10, 30, and 50 M
concentrations of the S-DOPA derivatives, as well as the H2S
donors ADT-OH and NaSH on glial-mediated neurotoxicity.
Fig. 5 shows the effect on SH-SY5Y viability of adding NaSH,
ADT-OH, L-DOPA, ()-deprenyl, ACS83, ACS84, ACS85, or
ACS86 to LPS/IFN-activated THP-1 cells (5A) or IFN-acti-
vated U373 cells (5B) at a standard concentration of 10 M. It
was found that the H2S-releasing agents ADT-OH and NaSH,
but not L-DOPA or ()-deprenyl, attenuated the neurotoxicity
in an incubation time-dependent manner. This is shown both
by theMTT assay (upper panels) and LDH assay (lower panels).
The four S-DOPA derivatives ACS83, ACS84, ACS85, and
ACS86 were comparably protective to NaSH and ADT-OH.
Complete data showing the results at 1, 3, 10, 30, and 50M, and
2, 4, 8, and 12 h pretreatment are shown in supplemen-
tal Figs. S4 and S5. Again, the results were highly similar for all
FIGURE 2. Intracellular (A) and extracellular (B) H2S levels (nmol/ml) after treatmentwith 10MACS50 in the presence of 1mMhydroxylamine. Values
are mean S.E., n 4.
FIGURE 3. H2S levels (mol/g protein) generated by isolated functional
mitochondria in human U373 cells after treatment with 10 M ADT-OH,
ACS48, ACS50, ACS5, ACS81, or ()-deprenyl. Values are mean  S.E.,
n 4.
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the SH-donors and all the S-DOPA derivatives in their concen-
tration and incubation time dependence.
The 8-h time period shown in Fig. 5 demonstrated a robust
effect of THP-1 and U373 cells, so it was deemed optimum
for showing comparative effects using human microglia
and astrocytes. It was found that the protective effect of pre-
treatment with NaSH and the S-DOPAs (10 M, 8 h) was
comparable in human microglia and astrocytes to that found
for THP-1 and U373 cells (Fig. 6A: microglia and 6B: astro-
cytes). MTT data are shown in the upper panels and LDH
release data in the lower panels. More detailed experimental
data (3, 10, and 50 M; 8 h of preincubation) showing com-
parable effects at differing concentrations are shown in
supplemental Fig. S6.
Inflammatory stimulation ofmicroglia or THP-1 cells causes
them to release the inflammatory cytokines TNF and IL-6, as
well as to generate neurotoxic nitrite ions. Fig. 7 shows the
effect of treatmentwithNaSH,ADT-OH, and the four S-DOPA
compounds (10 M each, 8 h of preincubation) on THP-1
release of TNF (Fig. 7A), IL-6 (Fig. 7C), and nitrite ions (Fig.
7E), and on human microglial release of TNF (Fig. 7B), IL-6
(Fig. 7D) and nitrite ions (Fig. 7F). There was a substantially
lower release of nitrite ions by stimulated microglia compared
withTHP-1 cells, even allowing for the 10-fold lower number of
microglial cells that were seeded. This is perhaps related to the
reported poor ability of humanmicroglia to express iNOS.Nev-
ertheless there were significant differences between the release
of these materials in both types of cells: (1) between stimulated
FIGURE 4.A, effect of direct treatmentwithNaSH, L-DOPA, ACS83, ACS84, ACS85, or ACS86 onGSH levels in SH-SY5Y cells. After SH-SY5Y cellswere treatedwith
NaSH, L-DOPA, ACS83, ACS84, ACS85, or ACS86 (10Meach) for 8 h and subsequently exposed to THP-1 orU373 conditionedmedium (CM) for 1 day, theywere
extracted tomeasure GSH levels. B and C, effect of direct treatment with NaSH, ADT-OH (ADT), L-DOPA, ACS83, ACS84, ACS85, or ACS86 on activities of MAOA
and MAO B in SH-SY5Y cells exposed to stimulated THP-1 or U373-conditioned medium (CM). After SH-SY5Y cells were treated with NaSH, L-DOPA, ACS83,
ACS84, ACS85, or ACS86 (10M each) for 8 h and subsequently exposed to THP-1 or U373 CM for 1 day, theywere extracted tomeasure activities of MAOA (B)
andMAOB (C). Notice that noneof the compounds inhibitedMAOA, but all of themsignificantly inhibitedMAOBexcept for L-DOPA.Notice also that therewas
significantly less inhibition when the SH-SY5Y cells were exposed to CM. Values are mean S.E., n 4. Two-way ANOVA was initially carried out to test the
significance among the treatment groups. The significance of differences was then adjusted by applying the Bonferroni test for multiple comparisons. *, p
0.01 for NaSH or all the ACS-treated groups compared with untreated group; **, p 0.01 exposed to media from stimulated THP-1 or U373 compared with
control media; and ***, p 0.01 exposed to stimulated THP-1 or U373 media treated with NaSH or all the ACS compounds compared with stimulated media
only.
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and unstimulated cells and (2)
between stimulated cells that were
untreated and stimulated cells that
were treated with NaSH, ADT-OH,
or any one of the S-DOPA com-
pounds (p  0.01). However,
L-DOPA or ()-deprenyl did not
affect the release of any of these
proinflammatorymediators (Fig. 7).
Fig. 8 shows comparable data for
IL-6 release from U373 cells (Fig.
8A) and cultured astrocytes (Fig.
8B). Cells were activated with IFN
as described under “Experimental
Procedures” and were then treated
similarly to the THP-1 and micro-
glial cells as shown in Fig. 5. In both
types of cells significant differences
were found: (1) for the release of
IL-6 from stimulated compared
with unstimulated cells and (2) for
stimulated cells treated with NaSH,
ADT-OH, or the four S-DOPA
compounds compared with stimu-
lated cells that were untreated (p 
0.01). Complete data showing a sim-
ilar concentration dependence of
the four donormoieties and the four
S-DOPA derivatives on H2S release
(3, 10, and 50 M; 8 h pretreatment)
are shown in supplemental Figs.
S7 and S8. Supplemental Fig. S9
shows that the viability of THP-1,
U373, microglia, and astrocytes was
unaffected by any of the eight S-do-
nating agents. Supplemental Fig.
S10 shows that the neuroprotective
effectswere additivewhen therewas
a combination of two S-DOPA
derivatives (i.e. ACS 83  84, ACS
84  85, ACS 84  86) compared
with the same derivatives alone.
DISCUSSION
In the present study, we exam-
ined the antioxidant and antiinflam-
matory properties of four H2S
donors (ACS48, ACS50, ACS5, and
ACS81 as well as ADT-OH), and
four L-DOPA hybrid compounds
synthesized from the four donors
(ACS83, ACS84, ACS85, and
ACDS86). They all demonstrated
therapeutic potential by being taken
up by human microglia, and astro-
cytes, as well as the humanTHP-1
U373 cell lines and then generating
intracellularH2S. TheH2S they gen-
FIGURE5.Effect on theviabilityof SH-SY5Ycells following treatmentwith supernatants fromstimulated
THP-1 cells (A) or U373 cells (B) that had been exposed to 10 M of the neuroprotective moieties as
described under “Experimental Procedures.” These were NaSH, the H2S-releasing dithiol-thione moiety
ADT-OH, ACS48, ACS50, ACS5, ACS81, ACS83, ACS84, ACS85, or ACS86pre-administered for (, 0 h) (o, 2 h), (z,
4 h), (p, 8 h), and (f, 12 h). L-DOPA or ()-deprenyl, which were without effect, served as the negative control
and NaSH as the positive control. Notice that the SH donors were equally protective and were comparable to
the the standard donor NaSH. Upper panels show MTT results whereas lower panels show LDH results. Values
are mean  S.E., n  4. Two-way ANOVA was carried out to test the significance of differences. Multiple
comparisons were followed with post-hoc Bonferroni tests. The time-dependent values were significantly
different from control (p 0.01) for NaSH and each of the S-donating compounds.
FIGURE 6. Effect of treatment with NaSH, ADT-OH, L-DOPA, ()-deprenyl, ACS48, ACS50, ACS5, ACS81,
ACS83, ACS84, ACS85, or ACS86 (10 M each, 8 h of preincubation) on SH-SY5Y cell viability changes
induced by activated humanmicroglia (A) or activated astrocytes (B) as followedbyMTT (upper panels)
andLDHrelease (lowerpanels) assays.Values aremean S.E.,n4.One-wayANOVAwas carriedout to test
the significance of differences. Multiple comparisons were followed with post-hoc Bonferroni tests where
appropriate. *, p 0.01 comparing the stimulated (ST) with the non-stimulated (NO-ST) group and **, p 0.01
comparing stimulated (ST) group with the S-DOPA treatment groups.
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erated acted in part to enhance levels of the classical antioxi-
dantGSH. They also inhibitedMAOB.Moreover, they acted as
antiinflammatory compounds by ameliorating the neurotoxic
effects of glial cell supernatants toward SH-SY5Y cells. Addi-
tionally, they inhibited release of the proinflammatory media-
tors TNF, IL-6, and nitrite ions (Figs. 7 and 8). The com-
pounds were equipotent, but L-DOPA was without effect in all
of these assays.
We have previously reported that depleting intracellular
GSHby inhibiting its synthetic enzyme-glutamylcysteine syn-
thase induces an inflammatory reaction in glial cells with con-
sequent neurotoxic effects (32). The
compounds described here could
help counteract the consequences
of depressed GSH production. Our
pilot in vivo data with ACS 84
showed that it reached the brain and
was substantially metabolized as
early as 1 h after iv administration to
a rat. Therewas amore than a 2-fold
increase in brain dopamine and a
1.4-fold increase in GSH. This dem-
onstrates that a significant amount
of the intact, and very lipophilic
ACS84, crosses the blood brain bar-
rier and is hydrolyzed in the brain
into its two components L-DOPA
and ACS50. Moreover the concom-
itant inhibition of the dopamine-
metabolizing enzyme MAO B, as
had previously been shown for
dithiolethiones (33), could contrib-
ute to sustain the high concentra-
tion of dopamine in brain. The
increase of GSH presumably results
from the H2S generated by metabo-
lism of the donor moiety. While
very preliminary, these data demon-
strate that these L-DOPA hybrids
may have therapeutic potential by
enhancing dopamine and GSH
levels.
Earlier studies have indicated that
H2S is a reducing agent that can
increase levels of intracellular gluta-
thione (14) thereby inhibiting oxi-
dative stress. It also decreases levels
of peroxynitrite-derived nitrated
proteins (34). ThusH2Smight block
oxidative stress-mediated cell death
in PD by directly or indirectly
detoxifying free radicals generated
fromoxidized L-DOPAcompounds.
As far as neuroinflammation is
concerned, it is well known that
areas affected in PD, especially the
substantia nigra, are characterized
by the presence of activated micro-
glia and activated astrocytes (4, 7–10, 35, 36). There is compa-
rable glial activation in animalmodels of PD (37). Evidence that
these reactive glial cells contribute to the neuronal degenera-
tion comes from epidemiological studies where persons taking
NSAIDs are reported to be relatively spared from PD (38, 39)
especially if combined with coffee (40). Such protection is also
reported for animal models of PD (37, 41).
The MPTP phenomena may be particularly revealing with
respect to the potential consequences of inducing SN inflam-
mation. Drug addicts who were originally exposed to MPTP
developed a relentlessly progressive parkinsonian syndrome.
FIGURE 7. Effect of treatment with NaSH, ADT-OH, L-DOPA, ()-deprenyl, ACS48, ACS50, ACS5, ACS81,
ACS83, ACS84, ACS85, or ACS86 (10Meach, 8 h of preincubation) on the released levels of TNF (A,B),
IL-6 (C,D) and nitrite ions (E, F) from THP-1 cells (A, C, E) or humanmicroglia (B,D, F). Values are mean
S.E., n 4. One-way ANOVAwas carried out to test the significance of differences. Multiple comparisons were
followed with post-hoc Bonferroni tests where appropriate. *, p 0.01 comparing the stimulated group with
the non-stimulated group (NO-ST) and **, p  0.01 comparing the stimulated group (ST) with the S-DOPA
treatment groups.
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Postmortem studies showed persistent inflammation up to
17 years following their last exposure to the toxin (35). This
human experience was duplicated in monkeys where inflam-
mation of the SN was demonstrated up to 14 years after their
last MPTP exposure (8). This suggests that inflammation of
the SN, once initiated, may be self sustaining. If this is the case,
antiinflammatory treatment may be essential to arresting pro-
gression of PD.
Our study demonstrates that inflammatory stimulation of
glial cells results in a 5–7-fold decrease in intracellular H2S (see
supplemental Fig. S11). This indicates an increase in intra-
cellular consumption as reactive processes are induced. These
experiments were performed in the presence of hydroxylamine
to suppress endogenousH2S synthesis byCBS. But in a previous
study (12) we showed that such inflammatory stimulation also
sharply reduced the expression of CBS. Therefore inflamma-
tory stimulation reduces intra-glial production of H2S while
at the same time increasing consumption. The result is a dep-
rivation of this endogenous anti-inflammatory and neuropro-
tective agent.
There are studies demonstrating that serum levels of homo-
cysteine, an intermediate of the trans-sulfuration pathway,
were increased in PD patients receiving L-DOPA (42–44). One
of the main enzymes responsible for hyperhomocysteinemia is
CBS, which is mainly expressed in astrocytes in brain (11, 12).
So it could be hypothesized that endogenous production ofH2S
is reduced in PD brain, thus compounding the potential dam-
age of oxidative stress associated with L-DOPA administration.
This provides additional rationale for designing methods of
supplementing H2S availability in PD.
We have previously shown that SH-SY5Y cells express
both MAO A and B (45). MAO B is primarily responsible for
oxidative degradation of dopamine (46, 47). Treatment with
NaSH and H2S-releasing moieties selectively inhibitedMAO
B (Fig. 4C). This could be one of the reasons why ACS84-
treated rats have higher dopamine levels than vehicle or
L-DOPA injected rats (Table 2). However, we could not exclude
that dopamine is generated from degradation of ACS84 in rats.
MAO B activity in SH-SY5Y cells was less inhibited in cells
exposed to the inflammatory effects
of THP-1- or U373 cell-conditioned
medium. This could be due to con-
sumption of the generated H2S
in stimulated cells, presumably
through oxidative reactions.
In conclusion, our data demon-
strate that H2S not only has anti-
inflammatory activity against the
glial toxicity which may be associ-
ated with the pathogenesis of PD
(36), but may also reduce the stress
induced by L-DOPA oxidation (14).
Furthermore, by inhibiting MAO B,
H2S-releasing L-DOPA compounds
could help restore the disease-
depleted dopamine levels. The
H2S-releasing L-DOPA derivatives
(S-DOPAs) described here repre-
sent compounds that can reach the brain and, in cells under
stress, deliver ameliorating SH ions in a time-dependentman-
ner. They have properties thatmake them candidates for future
treatment of PD. However the long term consequences of their
use will require much further study.
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